Pharmaceutical

Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Apr 26, 2025 - 06:00
Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds
The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.
Read the original article

Tags:

Previous Article

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

Next Article

MSD’s Gardasil sales slide further due to China constraints

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data

STAT+: Dana-Farber cancer researchers moving to retract...

Jan 20, 2024

STAT+: FDA approves new treatment from Biogen for rare form of ALS

STAT+: FDA approves new treatment from Biogen for rare ...

Apr 25, 2023

Exploring Melbourne’s booming life sciences sector

Exploring Melbourne’s booming life sciences sector

Jul 16, 2024